Table 2 Association between MCM2, Ki-67, and Gelsolin and Clinicopathological Characteristics in 128 Patients with NSCLC, RPCI, 1995–1999
From: Prognostic significance of MCM2, Ki-67 and gelsolin in non-small cell lung cancer
Clinicopathological Characteristics | Low MCM2 (n = 49) | High MCM2 (n = 79) | Low Ki-67 (n = 28) | High Ki-67 (n = 100) | Low GSN (n = 86) | High GSN (n = 42) |
|---|---|---|---|---|---|---|
Gender | Â | Â | Â | Â | Â | Â |
   Male | 19 (38.8%) | 51 (64.6%)** | 13 (46.4%) | 57 (57.0%) | 42 (48.8%) | 14 (33.3%)* |
   Female | 30 (61.2%) | 28 (35.4%) | 15 (53.6%) | 43 (43.0%) | 44 (51.2%) | 28 (66.7%) |
Race | Â | Â | Â | Â | Â | Â |
   Caucasians | 47 (95.9%) | 73 (92.4%) | 26 (92.9%) | 94 (94.0%) | 83 (96.5%) | 37 (88.1%) |
   Non-Caucasians | 2 (4.1%) | 6 (7.6%) | 2 (7.1%) | 6 (6.0%) | 3 (3.5%) | 5 (11.9%) |
Mean age (SD) Smoking status | 64.7 (9.2) | 63.9 (11.6) | 63.0 (10.9) | 64.6 (10.7) | 64.8 (9.6) | 63.2 (12.8) |
   Current | 18 (36.7%) | 35 (44.3%) | 11 (39.3%) | 42 (42.0%) | 34 (39.5%) | 19 (45.2%) |
   Former | 27 (55.1%) | 37 (46.8%) | 14 (50.0%) | 50 (50.0%) | 43 (50.0%) | 21 (50.0%) |
   Never | 4 (8.2%) | 7 (8.9%) | 3 (10.7%) | 8 (8.0%) | 9 (10.5%) | 2 (4.8%) |
Mean pack-years (SD) (a) | 47.9 (30.2) | 46.4 (29.4) | 45.6 (36.4) | 47.4 (27.6) | 44.6 (28.8) | 51.9 (31.0) |
Family history | Â | Â | Â | Â | Â | Â |
   No | 35 (71.4%) | 52 (65.8%) | 23 (82.1%) | 64 (64.0%) | 58 (67.4%) | 29 (69.0%) |
   Yes | 14 (28.6%) | 27 (34.2%) | 5 (17.9%) | 36 (36.0%) | 28 (32.6%) | 13 (31.0%) |
Pathology Stage | Â | Â | Â | Â | Â | Â |
   I | 30 (61.2%) | 45 (57.0%) | 16 (57.1%) | 59 (59.0%) | 52 (60.5%) | 23 (54.8%) |
   II | 15 (30.6%) | 16 (20.2%) | 8 (28.6%) | 23 (23.0%) | 22 (25.6%) | 9 (21.4%) |
   IIIA | 4 (8.2%) | 18 (22.8%) | 4 (14.3%) | 18 (18.0%) | 12 (14.0%) | 10 (23.8%) |
Tumor size | Â | Â | Â | Â | Â | Â |
   ≤3 cm | 22 (45.8%) | 27 (34.2%) | 12 (42.9%) | 37 (37.4%) | 35 (41.2%) | 14 (33.3%) |
   >3 cm | 26 (54.2%) | 52 (65.8%) | 16 (57.1%) | 62 (62.6%) | 50 (58.8%) | 28 (66.7%) |
Lymph node status | Â | Â | Â | Â | Â | Â |
   Negative | 34 (70.8%) | 47 (59.5%) | 18 (64.3%) | 63 (63.6%) | 58 (68.2%) | 23 (54.8%) |
   Positive | 14 (29.2%) | 32 (40.5%) | 10 (35.7%) | 36 (36.4%) | 27 (31.8%) | 19 (45.2%) |
Histology | Â | Â | Â | Â | Â | Â |
   Adenocarcinoma | 41 (83.7%) | 36 (45.6%)** | 20 (71.4%) | 57 (57.0%) | 56 (65.1%) | 21 (50.0%)* |
   Squamous | 3 (6.1%) | 36 (45.6%) | 6 (21.4%) | 33 (33.0%) | 23 (26.7%) | 16 (38.1%) |
   Large cell | 2 (4.1%) | 3 (3.8%) | 1 (3.6%) | 4 (4.0%) | 5 (5.8%) | 0 (0.0%) |
   Others | 3 (6.1%) | 4 (5.1%) | 1 (3.6%) | 6 (6.0%) | 2 (2.3%) | 5 (11.9%) |
Grade | Â | Â | Â | Â | Â | Â |
   Well differentiation | 1 (2.0%) | 2 (2.5%)* | 2 (7.1%) | 1(1.0%) | 1(1.1%) | 2(4.8%) |
   Mod. differentiation | 25 (51.1%) | 23 (29.1%) | 13 (46.4%) | 35 (35.0%) | 33 (38.4%) | 15 (35.7%) |
   Poor differentiation | 23 (46.9%) | 54 (68.4%) | 13 (46.4%) | 64 (64.0%) | 52 (60.5%) | 25 (59.5%) |
Performance Status | Â | Â | Â | Â | Â | Â |
   Without symptom | 32 (65.3%) | 55 (69.6%) | 21 (75.0%) | 66 (66.0%) | 61 (70.9%) | 26 (61.9%) |
   With symptom | 17 (34.7%) | 24 (30.4%) | 7 (25.0%) | 34 (34.0%) | 25 (29.1%) | 16 (38.1%) |
Weight loss (b) | Â | Â | Â | Â | Â | Â |
   No | 43 (87.8%) | 67 (84.8%) | 24 (85.7%) | 86 (86.0%) | 76 (88.4%) | 34 (81.0%) |
   Yes | 6 (12.2%) | 12 (15.2%) | 4 (14.3%) | 14 (14.0%) | 10 (11.6%) | 8 (19.0%) |
Mean survival in month (SD) | 49.8 (28.0) | 40.8 (25.7) | 50.0 (31.3) | 42.7 (25.4) | 48.0 (26.6) | 36.7 (26.1)* |